ANTI-HIV CHEMOTHERAPY: CURRENT STATE OF THE ART

@article{Clercq2004ANTIHIVCC,
  title={ANTI-HIV CHEMOTHERAPY: CURRENT STATE OF THE ART},
  author={E. Clercq},
  journal={Medicinal Chemistry Research},
  year={2004},
  volume={13},
  pages={439-478}
}
  • E. Clercq
  • Published 2004
  • Chemistry
  • Medicinal Chemistry Research
  • In recent years, significant progress has been made towards the chemotherapy (and ?prophylaxis) of HIV infections. This progress is situated at three different levels. (i) New anti-HIV drugs have been approved for clinical use and have entered the market: the virus entry inhibitor enfuvirtide (Fuzeon™), the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva™), the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir disoproxil fumarate (Viread™) and the HIV… CONTINUE READING
    19 Citations
    Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
    • Z. Wang, B. Wu, +4 authors Yun He
    • Chemistry, Medicine
    • Bioorganic & medicinal chemistry letters
    • 2006
    • 61
    Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
    • 16